Factors associated with survival of patients with solid Cancer alive after intensive care unit discharge between 2005 and 2013.
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Female
Follow-Up Studies
France
Hospital Mortality
/ trends
Hospitalization
/ statistics & numerical data
Humans
Intensive Care Units
/ statistics & numerical data
Male
Middle Aged
Neoplasms
/ drug therapy
Patient Discharge
/ statistics & numerical data
Prognosis
Prospective Studies
Retrospective Studies
Survival Rate
Time Factors
Anticancer treatments
Intensive care unit
Performance status
Prognosis
Solid cancer
Survival
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
05 Jan 2021
05 Jan 2021
Historique:
received:
03
07
2020
accepted:
01
12
2020
entrez:
6
1
2021
pubmed:
7
1
2021
medline:
15
5
2021
Statut:
epublish
Résumé
At intensive care unit (ICU) admission, the issue about prognosis of critically ill cancer patients is of clinical interest, especially after ICU discharge. Our objective was to assess the factors associated with 3- and 6-month survival of ICU cancer survivors. Based on the French OutcomeRea™ database, we included solid cancer patients discharged alive, between December 2005 and November 2013, from the medical ICU of the university hospital in Grenoble, France. Patient characteristics and outcome at 3 and 6 months following ICU discharge were extracted from available database. Of the 361 cancer patients with unscheduled admissions, 253 (70%) were discharged alive from ICU. The main primary cancer sites were digestive (31%) and thoracic (26%). The 3- and 6-month mortality rates were 33 and 41%, respectively. Factors independently associated with 6-month mortality included ECOG performance status (ECOG-PS) of 3-4 (OR,3.74; 95%CI: 1.67-8.37), metastatic disease (OR,2.56; 95%CI: 1.34-4.90), admission for cancer progression (OR,2.31; 95%CI: 1.14-4.68), SAPS II of 45 to 58 (OR,4.19; 95%CI: 1.76-9.97), and treatment limitation decision at ICU admission (OR,4.00; 95%CI: 1.64-9.77). Interestingly, previous cancer chemotherapy prior to ICU admission was independently associated with lower 3-month mortality (OR, 0.38; 95%CI: 0.19-0.75). Among patients with an ECOG-PS 0-1 at admission, 70% (n = 66) and 61% (n = 57) displayed an ECOG-PS 0-2 at 3- and 6-months, respectively. At 3 months, 74 (55%) patients received anticancer treatment, 13 (8%) were given exclusive palliative care. Factors associated with 6-month mortality are almost the same as those known to be associated with ICU mortality. We highlight that most patients recovered an ECOG-PS of 0-2 at 3 and 6 months, in particular those with a good ECOG-PS at ICU admission and could benefit from an anticancer treatment following ICU discharge.
Sections du résumé
BACKGROUND
BACKGROUND
At intensive care unit (ICU) admission, the issue about prognosis of critically ill cancer patients is of clinical interest, especially after ICU discharge. Our objective was to assess the factors associated with 3- and 6-month survival of ICU cancer survivors.
METHODS
METHODS
Based on the French OutcomeRea™ database, we included solid cancer patients discharged alive, between December 2005 and November 2013, from the medical ICU of the university hospital in Grenoble, France. Patient characteristics and outcome at 3 and 6 months following ICU discharge were extracted from available database.
RESULTS
RESULTS
Of the 361 cancer patients with unscheduled admissions, 253 (70%) were discharged alive from ICU. The main primary cancer sites were digestive (31%) and thoracic (26%). The 3- and 6-month mortality rates were 33 and 41%, respectively. Factors independently associated with 6-month mortality included ECOG performance status (ECOG-PS) of 3-4 (OR,3.74; 95%CI: 1.67-8.37), metastatic disease (OR,2.56; 95%CI: 1.34-4.90), admission for cancer progression (OR,2.31; 95%CI: 1.14-4.68), SAPS II of 45 to 58 (OR,4.19; 95%CI: 1.76-9.97), and treatment limitation decision at ICU admission (OR,4.00; 95%CI: 1.64-9.77). Interestingly, previous cancer chemotherapy prior to ICU admission was independently associated with lower 3-month mortality (OR, 0.38; 95%CI: 0.19-0.75). Among patients with an ECOG-PS 0-1 at admission, 70% (n = 66) and 61% (n = 57) displayed an ECOG-PS 0-2 at 3- and 6-months, respectively. At 3 months, 74 (55%) patients received anticancer treatment, 13 (8%) were given exclusive palliative care.
CONCLUSIONS
CONCLUSIONS
Factors associated with 6-month mortality are almost the same as those known to be associated with ICU mortality. We highlight that most patients recovered an ECOG-PS of 0-2 at 3 and 6 months, in particular those with a good ECOG-PS at ICU admission and could benefit from an anticancer treatment following ICU discharge.
Identifiants
pubmed: 33402107
doi: 10.1186/s12885-020-07706-3
pii: 10.1186/s12885-020-07706-3
pmc: PMC7786972
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
9Références
Ann Oncol. 2014 Sep;25(9):1829-1835
pubmed: 24950981
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Chest. 2014 Oct;146(4):916-923
pubmed: 25117058
Crit Care Resusc. 2017 Jun;19(2):159-166
pubmed: 28651512
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
Intensive Care Med. 2010 Jul;36(7):1188-95
pubmed: 20221751
Lung Cancer. 2015 Aug;89(2):218-21
pubmed: 26022271
Ann Intensive Care. 2018 Mar 27;8(1):40
pubmed: 29582210
J Clin Oncol. 2017 Oct 20;35(30):3484-3515
pubmed: 28806116
Intensive Care Med. 2014 Oct;40(10):1570-2
pubmed: 25160033
CA Cancer J Clin. 2016 Nov 12;66(6):496-517
pubmed: 27348695
J Intensive Care Med. 2019 Jun;34(6):435-448
pubmed: 30165779
JAMA. 1993 Dec 22-29;270(24):2957-63
pubmed: 8254858
Ann Intensive Care. 2018 Nov 14;8(1):108
pubmed: 30430269
Intensive Care Med. 2009 Dec;35(12):2044-50
pubmed: 19768453
Cancer Epidemiol. 2018 Oct;56:97-105
pubmed: 30125884
Intensive Care Med. 2015 Oct;41(10):1763-72
pubmed: 26149302
Crit Care Med. 2017 Oct;45(10):1668-1676
pubmed: 28682838
J Clin Oncol. 2016 Aug 10;34(23):2784-96
pubmed: 27247222
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Eur J Cancer Care (Engl). 2010 Mar;19(2):260-6
pubmed: 19709168
Crit Care. 2009;13(1):R15
pubmed: 19200368
Intensive Care Med. 2020 Aug 7;:
pubmed: 32770267
QJM. 2018 Jun 1;111(6):379-383
pubmed: 29534214
Ann Intensive Care. 2017 Dec;7(1):26
pubmed: 28265980
Ann Intensive Care. 2011 Mar 23;1(1):5
pubmed: 21906331
Intensive Care Med. 2014 Oct;40(10):1409-28
pubmed: 25223853
ESMO Open. 2017 Oct 12;2(4):e000105
pubmed: 29259818
Intensive Care Med. 2005 Mar;31(3):408-15
pubmed: 15678310
Intern Med J. 2014 Nov;44(11):1087-94
pubmed: 25132619
Intensive Care Med. 1999 Jul;25(7):686-96
pubmed: 10470572
Crit Care Med. 2016 Jul;44(7):1327-37
pubmed: 26998653
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593